1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
Next-Generation Gynecological Cancer Diagnostics Market - A Global Market and Regional Analysis: Focus on Technology, Product Type, End User, and Country Analysis - Analysis and Forecast, 2020-2031

Next-Generation Gynecological Cancer Diagnostics Market - A Global Market and Regional Analysis: Focus on Technology, Product Type, End User, and Country Analysis - Analysis and Forecast, 2020-2031

  • March 2022
  • 231 pages
  • ID: 6248270
  • Format: PDF
  • BIS Research

Summary

Table of Contents

Global Next-Generation Gynecological Cancer Diagnostics Market to Reach $5.66 Billion by 2031

Market Report Coverage - Next-Generation Gynecological Cancer Diagnostics

Market Segmentation

• By Product Type - Products and Services
• By Technology - Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Others
• By Indication - Ovarian Cancer, Cervical Cancer, and Uterine Cancer
• By End User - Hospitals and Ambulatory Centers, Diagnostic Laboratories, Academic and Research Institutes, and Other End Users

Regional Segmentation

• North America - U.S., Canada
• Europe - Germany, U.K., France, Italy, Spain, The Netherlands, and Rest-of-Europe
• Asia-Pacific - China, Australia, Japan, India, South Korea, and Rest-of-Asia-Pacific
• Latin America - Mexico, Brazil, and Rest-of-Latin-America
• Rest-of-the-World

Market Growth Drivers

• Subsequent Decline in Next-Generation Sequencing (NGS) Cost
• Increased Recommendations from Government Organizations and Scientific Societies
• Increased Awareness and Shift Toward Personalized Medicine

Market Challenges

• Limited Food and Drug Administration (FDA) Approved Next-Generation Sequencing (NGS) tests
• Complexities Involved with Overall Next-Generation Sequencing (NGS) Process and Result Interpretation
• Reimbursement Challenges Across the Countries

Market Opportunities

• Increased Market Investments and Government Funded Projects
• Next-Generation Sequencing (NGS) Acceptance by Emerging Nations

Key Companies Profiled

Agilent Technologies, Inc., ARUP Laboratories, BGI Genomics, CENTOGENE N.V., F. Hoffmann-La Roche Ltd, Fulgent Genetics, Inc., Illumina, Inc., Invitae Corporation, Konica Minolta, Inc., Laboratory Corporation of America Holdings, Myriad Genetics, Inc., OPKO Health, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report:
• Which gynecological cancers have been considered in the report?
• What are the key milestones in the development of next-generation gynecological cancer diagnostics?
• What is the scope of next-generation gynecological cancer diagnostics in the future?
• What are the major market drivers, restraints, and opportunities in the global next-generation gynecological cancer diagnostics market?
• What are the key developmental strategies that are being implemented by the key players to sustain this market?
• What is the impact of COVID-19 on the next-generation gynecological cancer diagnostics market?
• What are the guidelines implemented by different government bodies to regulate the approval of next-generation gynecological cancer diagnostics panels and assays?
• How are next-generation gynecological cancer diagnostics being utilized for the development of personalized medicine?
• What is the role of biomarkers in next-generation gynecological cancer diagnostics?
• How will the investments by public and private companies and government organizations affect the global next-generation gynecological cancer diagnostics market?
• What was the market size of the leading segments and sub-segments of the global next-generation gynecological cancer diagnostics market in 2020?
• How will the industry evolve during the forecast period 2021-2031?
• What will be the growth rate of the next-generation gynecological cancer diagnostics market during the forecast period 2021-2031?
• How will each of the segments of the global next-generation gynecological cancer diagnostics market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2031?
• What is the market size of the next-generation gynecological cancer diagnostics market in different countries of the world?
• Which region is expected to contribute to the highest sales of the next-generation gynecological cancer diagnostics market?
• What are the reimbursement scenarios and regulatory structures for the next-generation gynecological cancer diagnostics market in different regions?
• What are the key strategies incorporated by the players of the global next-generation gynecological cancer diagnostics market to sustain the competition and retain their supremacy?

Market Overview

Ovarian, cervical, and uterine cancer are the most common gynecological malignancies among women worldwide.Cervical cancer is the fourth most frequently occurring cancer in women.

It is anticipated that cervical cancer cases will increase from approximately 580,000 in 2018 to 700,000 in 2030, with a rise in the annual number of deaths from 311,000 to 400,000.Gynecological cancers are a result of genomic aberrations controlled by epigenetic factors, acquired and heritable mutations, and transcriptional deviations.

A comprehensive understanding of the genomic and molecular framework of gynecologic malignancies is critical in the evolution of potent biomarkers for detection and prevention, molecular profiling, and the development of personalized treatment strategies.

Traditionally, genetic analysis of gynecological malignancies was carried out by analyzing small, single portions of deoxyribonucleic acid (DNA), referred to as Sanger sequencing.Advanced molecular genetic testing, including next-generation sequencing, microarray, polymerase chain reaction, have contributed significantly to deciphering the molecular profile of gynecological cancers in recent years.

Advancements in the field of sequencing technologies have supported researchers and clinicians to harness knowledge pertaining to these underlying mutations, which further helped the stakeholders to discover biomarkers for guiding targeted therapeutic decisions.

The purpose of this study is to gain a holistic view of the next-generation gynecological cancer diagnostics market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market.The study defines the products and services utilized for next-generation gynecological cancer diagnostics to improve prognosis and quality of life among women.

Mutation molecular profiling is critical for the identification and characterization of unique mutations to facilitate disease manifestation and progression.Comprehensive profiling of biological samples, particularly blood and tissues, can help researchers and clinicians identify specific biomarkers that signify a particular disease.

The study aims at deciphering the potential of next-generation gynecological cancer diagnostics in the field of research and diagnostics and its critical role in bolstering the current genomic era to enable personalized medicine in routine healthcare settings.

The report includes an in-depth examination of the key players and recent developments taking place in this market.Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

It also aims at answering various aspects of the global next-generation gynecological cancer diagnostics market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Within the research report, the market has been segmented into ‘product type,’ ‘technology,’ ‘indication,’ ‘end user,’ and ‘regions.’. Each of these segments covers the inclination of the market revenue, underlying patterns, snapshot of the market over the projected years, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The global next-generation gynecological cancer diagnostics market is currently budding due to the presence of various juggernauts such as Laboratory Corporation of America Holdings, F. Hoffmann-La Roche Ltd, Illumina, Inc., Agilent Technologies, Inc., BGI, and PerkinElmer Inc., as well as other medium and small-medium enterprises, that are offering a wide range of next-generation gynecological cancer diagnostics products and services in the market. Several companies are attempting to enter the market and sustain themselves in the competition by adopting different strategies varying from partnerships and collaborations to business expansions and product launches.

Countries Covered
• North America
• U.S.
• Canada
• Europe
• Germany
• Italy
• France
• U.K.
• Spain
• Netherlands
• Rest-of-Europe
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest-of-Asia-Pacific
• Latin America
• Brazil
• Mexico
• Rest-of-Latin America
• Rest-of-the-World

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

2022-2026 France Cancer Diagnostics Market Database--Sales and Market Shares for Reagent and Instrument Suppliers, Major Tumor Markers Volume and Sales Segment Forecasts

  • $ 2500
  • June 2022

2022-2026 France Cancer Diagnostics Market Database--Sales and Market Shares for Reagent and Instrument Suppliers, Major Tumor Markers Volume and Sales Segment Forecasts This unique database provides ...

  • France
  • Hormone
  • Cancer Diagnostics
  • Industry analysis

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on